Suppr超能文献

产前皮质类固醇单次给药与每周给药疗程:安全性和疗效评估

Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy.

作者信息

Wapner Ronald J, Sorokin Yoram, Thom Elizabeth A, Johnson Francee, Dudley Donald J, Spong Catherine Y, Peaceman Alan M, Leveno Kenneth J, Harper Margaret, Caritis Steve N, Miodovnik Menachem, Mercer Brian, Thorp John M, Moawad Atef, O'Sullivan Mary Jo, Ramin Susan, Carpenter Marshall W, Rouse Dwight J, Sibai Baha, Gabbe Steven G

机构信息

Department of Obstetrics and Gynecology, Drexel University College of Medicine, Philadelphia, PA, USA.

出版信息

Am J Obstet Gynecol. 2006 Sep;195(3):633-42. doi: 10.1016/j.ajog.2006.03.087. Epub 2006 Jul 17.

Abstract

OBJECTIVE

The purpose of this study was to determine if weekly corticosteroids improve neonatal outcome without undue harm.

STUDY DESIGN

Women 23 to 32 weeks receiving 1 course of corticosteroids 7 to 10 days prior were randomized to weekly betamethasone or placebo.

RESULTS

The study was terminated by the independent data and safety monitoring committee with 495 of the anticipated 2400 patients enrolled. There was no significant reduction in the composite primary morbidity outcome (8.0% vs 9.1%, P = .67). Repeated courses significantly reduced neonatal surfactant administration (P = .02), mechanical ventilation (P = .004), CPAP (P = .05), pneumothoraces (P = .03). There was no significant difference in mean birth weight or head circumference. The repeat group had a reduction in multiples of the birth weight median by gestational age (0.88 vs 0.91) (P = .01) and more neonates weighing less than the 10th percentile (23.7 vs 15.3%, P = .02). Significant weight reductions occurred for the group receiving > or = 4 courses.

CONCLUSION

Repeat antenatal corticosteroids significantly reduce specific neonatal morbidities but do not improve composite neonatal outcome. This is accompanied by reduction in birth weight and increase in small for gestational age infants.

摘要

目的

本研究旨在确定每周使用皮质类固醇激素是否能改善新生儿结局且无不当危害。

研究设计

孕周为23至32周且在7至10天前接受过1个疗程皮质类固醇激素治疗的女性被随机分为每周接受倍他米松或安慰剂治疗组。

结果

该研究在纳入预期的2400例患者中的495例后,由独立数据和安全监测委员会终止。复合主要发病结局无显著降低(8.0%对9.1%,P = 0.67)。重复疗程显著减少了新生儿表面活性剂的使用(P = 0.02)、机械通气(P = 0.004)、持续气道正压通气(P = 0.05)、气胸(P = 0.03)。平均出生体重或头围无显著差异。重复疗程组按胎龄计算的出生体重中位数倍数有所降低(0.88对0.91)(P = 0.01),且体重低于第10百分位数的新生儿更多(23.7%对15.3%,P = 0.02)。接受≥4个疗程治疗的组体重显著降低。

结论

重复产前使用皮质类固醇激素可显著降低特定新生儿发病率,但不能改善复合新生儿结局。这伴随着出生体重降低和小于胎龄儿数量增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验